Prognostic Intake of Molecular Markers in Lung Cancer The Pulmonologist Point Of View
| Autor: | Laura Mazilu, Stefan Dumitrache-Rujinski, Oana Cristina Arghir, Ioana Gogonea, Doina Tofolean, Elena Dantes, Ariadna Petronela Fildan |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Oncology
medicine.medical_specialty molecular markers business.industry Pulmonologist respiratory system tnm stage medicine.disease General Biochemistry Genetics and Molecular Biology respiratory tract diseases lung cancer 03 medical and health sciences 0302 clinical medicine 030228 respiratory system 030220 oncology & carcinogenesis Internal medicine medicine Medicine Lung cancer business |
| Zdroj: | ARS Medica Tomitana, Vol 23, Iss 4, Pp 180-183 (2017) |
| ISSN: | 1841-4036 |
| DOI: | 10.1515/arsm-2017-0033 |
| Popis: | Lung cancer remains one of the most frequent pathologies in Pulmonology Departments. Tumor extension, histopathological types, and treatment influence the prognosis and survival in lung cancer. Five years survival dramatically decreases for the 4th-stage of the disease. Non-small cell lung cancer (NSCLC) represents the vast majority of lung cancers. In the last decades, important findings have been made on identifying standardized molecular biomarkers that control tumor growth in lung adenocarcinoma. The discovery of new drugs led to the increased survival, even in extensive forms of the disease. The greatest advances could be obtained by targeting EGFR genetic mutations or EML4-ALK translocate in patients diagnosed with adenocarcinoma lung cancer |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|